Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Revenue of $3.14M

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q4 revenue of $3.14 million, versus $0 reported last year.

Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49